Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Evidence for the Use of 11-keto-beta-boswellic acid in Colitis

11-keto-beta-boswellic acid (KBA) is one of the major bioactive constituents of Boswellia serrata (frankincense). The resin of this plant has a long history in traditional medicine for treating inflammatory conditions, including bowel diseases. However, the scientific interest in KBA specifically for colitis stems from its potent anti-inflammatory properties, which have been demonstrated in preclinical studies.

Several animal studies have shown that KBA and related boswellic acids inhibit key inflammatory pathways, such as 5-lipoxygenase and NF-κB, which are implicated in the pathogenesis of colitis. In rodent models of colitis (e.g., induced by dextran sulfate sodium or acetic acid), KBA has been observed to reduce inflammation, decrease disease severity, and improve colon histology.

Human clinical trials on Boswellia serrata extracts (which contain KBA as a major component) have been conducted for ulcerative colitis and have shown beneficial effects compared to placebo and, in some studies, to standard therapies like sulfasalazine. However, these trials generally used whole extracts rather than isolated KBA, and sample sizes have been modest.

While there is no substantial traditional use specifically of KBA for colitis, there is moderate scientific support for its role in managing inflammatory bowel diseases, primarily based on preclinical data and some small human trials with Boswellia extracts. More rigorous and larger clinical studies are needed to confirm its efficacy and safety.

More about 11-keto-beta-boswellic acid
More about Colitis

Other ingredients used for Colitis

Other health conditions supported by 11-keto-beta-boswellic acid

Products containing 11-keto-beta-boswellic acid